A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation (P8-3.016)
To evaluate the safety, tolerability and pharmacokinetic profile of single and multiple ascending doses of CVN293 in healthy volunteers.
Authors
- Louise Dickson (ORCID: https://orcid.org/0000-0003-0550-7495)
- Nicola Brice (ORCID: https://orcid.org/0000-0003-4533-9369)
- Mwesige Charles (ORCID: https://orcid.org/0000-0001-9330-6487)
- Roberto Tolando
- Philip Kremer
- Claudia Scholl (ORCID: https://orcid.org/0000-0001-6768-322X)
- Mark Carlton
- Martin Bexon (ORCID: https://orcid.org/0000-0002-5361-4343)
- Kim L. Matthews
- Graham Scott
- Lee A. Dawson
- Sagar A. Vaidya
- Jesminne Castricum
- Dino Ossola
Institutions
- Leiden University Medical Center (NL)
- Centre for Human Drug Research (NL)
- Bexon Clinical Consulting (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210912
- Primary Topic
- Macrophage Migration Inhibitory Factor
- Type
- article
- Field-Weighted Citation Impact
- 0.00